RealPatient

Tisa-cel shows durable efficacy and favorable safety1−7

In pediatric, adolescent and young adult ALL patients ≤25 years
in both the ELIANA trial and RWE, including subgroups of:

Children <3 years4,5

Post-transplant relapse or ≥2 relapses on therapy1−3

High-risk patients including with Down Syndrome and CNS disease6,7

  • References: 1. Rives S et al. European Haematology Association EHA 2022 Congress, 9‒12 June 2022, Vienna, Austria. Abstract S112.
  • 2. John S et al. Tandem Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR 2023, 15‒19 February 2023, Orlando, FL. Abstract 45.
  • 3. Tisagenlecleucel Summary of Product Characteristics. Nuremberg, Germany: Novartis Pharma GmbH; 2022.
  • 4. Moskop A et al. Blood Adv 2022;6(14):4251−4255.
  • 5. Ghorashian S et al. Lancet Haematol 2022;9(10):e766−e775.
  • 6. Maude SL et al. Leukemia. 2022;36:1508–1515.
  • 7. Fabrizio VA et al. Blood Adv 2022;6(2):600−610.